Diabetic neuropathy.
Conditions
Interventions
Intervention 1: After covering the perianal bilateral surface of the foot and the front of the ankle with 2% lidocaine ointment, a total of 240 units of botulinum toxin A must be administered (120 uni
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Definite diabetic neuropathy in the plantar area of ??both feet confirmed by NCV. diabetes at least for three years Consistency of the patient's medication for diabetic neuropathy for at least one month before entering the study Filling out a personal consent form to enter the study
Exclusion criteria
Exclusion criteria: Having an underlying disease involving the peripheral nerves that causes symptoms similar to diabetic neuropathy in the plantar area. Change in the patient's medication for diabetic neuropathy during at least one month before entering the study History of myasthenia gravis Allergy to botulinum toxin kidney dysfunction Having a history of alcohol consumption Opioid addiction Presence of pain with a typical dermatomal pattern caused by radiculopathy Lack of patient consent to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain and quality of life and sleep quality of patients. Timepoint: at the begining of the study and in 1-4-8-12 week after intervention. Method of measurement: Evaluation of changes in scores of VAS, PSQI, SF-36 questionnaires. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactYasaman malekzade
Shahid Beheshti University of Medical Sciences
Outcome results
None listed